Cover Image
市場調查報告書

歐洲的癲癇治療藥市場:2015∼2019年

Epilepsy Drugs Market in Europe - Market Analysis 2015-2019

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 341151
出版日期 內容資訊 英文 64 Pages
訂單完成後即時交付
價格
Back to Top
歐洲的癲癇治療藥市場:2015∼2019年 Epilepsy Drugs Market in Europe - Market Analysis 2015-2019
出版日期: 2015年09月30日 內容資訊: 英文 64 Pages
簡介

癲癇是一系列腦部疾病,從良性到惡性、嚴重危及生命的症狀都有。造成的原因五花八門,有腦畸形和腫瘤引起的腦膜炎,高風險妊娠,出生時的外傷等。歐洲的癲癇治療藥市場預測在2014∼2019年間將以年複合成長率3.22%擴大。

本報告提供歐洲的癲癇治療藥市場現狀及2015∼2019年的成長預測相關調查,為您彙整市場規模,收益趨勢,各產品,各地區趨勢,及主要供應商簡介等資料。

第1章 摘要整理

第2章 本報告的範圍

第3章 市場調查方法

第4章 簡介

第5章 癲癇:概要

  • 關於癲癇
  • 癲癇的種類
  • 症狀
  • 診斷
  • 流行病學
  • 經濟負擔

第6章 產品研發線

第7章 市場環境

  • 市場概要
  • 德國的癲癇治療藥市場
  • 英國的癲癇治療藥市場
  • 波特的五力分析

第8章 各製劑市場區隔

第9章 推動市場的要素

  • 未滿足需求
  • 患者人口的增加
  • 有潛力的藥劑開發平台

第10章 推動市場要素的影響

第11章 市場課題

  • 專利失效
  • 嚴格的法律規章指南
  • 伴隨癲癇的社會歧視眼光

第12章 促進要素與課題的影響

第13章 市場趨勢

  • 已上市藥物的再製作
  • 新世代抗癲癇藥的登場

第14章 供應商環境

  • 競爭模式
  • 市場佔有率分析:2014年
  • 其他值得注意的供應商

第15章 主要供應商分析

  • Eisai
  • GlaxoSmithKline
  • Pfizer
  • UCB

第16章 附錄

第17章 關於Technavio

圖表

目錄
Product Code: IRTNTR7242

About epilepsy

Epilepsy refers to a spectrum of brain disorders manifested by benign to severe, disabling, and life-threatening symptoms. It is caused by factors ranging from brain malformations and tumors to meningitis, high-risk pregnancies, and trauma during birth. When the underlying cause of the disease is unidentified, as is witnessed in the majority of cases, it is known as idiopathic epilepsy. An imbalance between the inhibitory and excitatory signals of the brain, leading to a sudden onset of excitation, results in seizures.

Technavio's analysts forecast the epilepsy drugs market in Europe to grow at a CAGR of 3.22% over the period 2014-2019.

Covered in this report

The report includes the present scenario and the growth prospects of the epilepsy drugs market in Europe for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment of epilepsy.

Technavio's report, Epilepsy Drugs Market in Europe 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. It covers the market size and forecast as well as market segmentation and pipeline landscape. The report includes a discussion of the key vendors operating in this market.

Key vendors

  • Eisai
  • GlaxoSmithKline
  • Pfizer
  • UCB

Other Prominent Vendors

  • AbbVie
  • Janssen Pharmaceuticals
  • Lundbeck
  • Meda
  • Novartis
  • Roche
  • Shire
  • Sunovion Pharmaceuticals
  • Supernus Pharmaceuticals
  • Upsher-Smith
  • Valeant Pharmaceuticals

Market driver

  • Unmet medical needs
  • For a full, detailed list, view our report

Market challenge

  • Patent expiry
  • For a full, detailed list, view our report

Market trend

  • Reformulation of marketed drugs
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Epilepsy: An overview

  • About the disease
  • Types of epilepsy
  • Signs and symptoms
  • Diagnosis
  • Epidemiology
  • Economic burden

PART 06: Pipeline portfolio

  • Key information of few pipeline candidates

PART 07: Market landscape

  • Market overview
  • Epilepsy drugs market in Germany
  • Epilepsy drugs market in the UK
  • Five forces analysis

PART 08: Market segmentation by generation of drugs

  • Segmentation of epilepsy drugs market in Europe by generation of drugs

PART 09: Market drivers

  • Unmet medical needs
  • Rise in patient population
  • Promising drug pipeline

PART 10: Impact of drivers

PART 11: Market challenges

  • Expiry of patents
  • Stringent regulatory guidelines
  • Social stigma associated with epilepsy

PART 12: Impact of drivers and challenges

PART 13: Market trends

  • Reformulation of marketed drugs
  • Emergence of new-generation anti-epileptic drugs

PART 14: Vendor landscape

  • Competitive scenario
  • Market share analysis 2014
  • Other prominent vendors

PART 15: Key vendor analysis

  • Eisai
  • GlaxoSmithKline
  • Pfizer
  • UCB

PART 16: Appendix

  • List of abbreviations

PART 17: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Cost per person in Europe 2010
  • Exhibit 03: Pipeline portfolio
  • Exhibit 04: Epilepsy drugs market in Europe 2014-2019 ($ millions)
  • Exhibit 05: Epilepsy drugs market in Europe 2014
  • Exhibit 06: Epilepsy drugs market in Germany 2014-2019 ($ millions)
  • Exhibit 07: Epilepsy drugs market in the UK 2014-2019 ($ millions)
  • Exhibit 08: Five forces analysis
  • Exhibit 09: Segmentation of epilepsy drugs market in Europe by generation of drugs
  • Exhibit 10: Impact of drivers
  • Exhibit 11: Impact of drivers and challenges
  • Exhibit 12: Eisai: Key takeaways
  • Exhibit 13: Eisai: Fycompa product profile
  • Exhibit 14: Eisai: Revenue of Fycompa in EMEA 2013 and 2014 ($ millions)
  • Exhibit 15: Eisai: Inovelon product profile
  • Exhibit 16: Eisai: Revenue of Inovelon in EMEA 2013 and 2014 ($ millions)
  • Exhibit 17: Eisai: Zebinix product profile
  • Exhibit 18: Eisai: Revenue of Zebinix in EMEA 2013 and 2014 ($ millions)
  • Exhibit 19: Eisai: Zonegran product profile
  • Exhibit 20: Eisai: Revenue of Zonegran 2013 and 2014 ($ millions)
  • Exhibit 21: GlaxoSmithKline: Key takeaways
  • Exhibit 22: GlaxoSmithKline: Lamictal product profile
  • Exhibit 23: GlaxoSmithKline: Revenue of Lamictal in Europe 2011-2014 ($ millions)
  • Exhibit 24: GlaxoSmithKline: Trobalt product profile
  • Exhibit 25: Pfizer: Key takeaways
  • Exhibit 26: Pfizer: Lyrica product profile
  • Exhibit 27: Pfizer: Revenue of Lyrica 2011-2014 ($ millions)
  • Exhibit 28: Pfizer: Neurontin product profile
  • Exhibit 29: Pfizer: Revenue of Neurontin 2011-2013 ($ millions)
  • Exhibit 30: UCB: Key takeaways
  • Exhibit 31: UCB: Keppra product profile
  • Exhibit 32: UCB: Revenue of Keppra in Europe 2011-2014 ($ millions)
  • Exhibit 33: UCB: Vimpat product profile
  • Exhibit 34: UCB: Revenue of Vimpat in Europe 2011-2014 ($ millions)
  • Exhibit 35: UCB: Product segmentation by revenue 2014
  • Exhibit 36: UCB: Product segmentation by revenue 2013 and 2014
  • Exhibit 37: UCB: Geographical segmentation by revenue 2014
  • Exhibit 38: UCB: Geographical segmentation by revenue 2013 and 2014
Back to Top